Biogen to present litifilimab lupus data at dermatology meeting

March 19, 2026 7:30 AM

Biogen Inc. (NASDAQ: BIIB) announced it will present late-breaking data from its AMETHYST Phase 2 study of litifilimab for cutaneous ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found